Editas to enter clinic with in vivo CRISPR therapy

Editas Medicine Inc. (NASDAQ:EDIT) plans to begin a Phase I/II trial of its CRISPR therapeutic EDIT-101 to treat Leber congenital amaurosis type 10 (LCA10) after FDA cleared its IND. EDIT-101 would be the first in vivo CRISPR therapy to enter clinical trials, according to the company.

Editas and its partner Allergan plc (NYSE:AGN) plan to enroll 10 to 20 adult and pediatric patients with LCA10 in an open label, dose-escalation study. The trial will evaluate both efficacy and safety, and will measure vision loss in the patients, Editas spokesperson Cristi Barnett told BioCentury. Barnett declined to disclose the trial's expected start date...